[HTML][HTML] Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis
K Shailubhai, V Palejwala, KP Arjunan… - World journal of …, 2015 - ncbi.nlm.nih.gov
AIM: To evaluate the effect of orally administered plecanatide or dolcanatide, analogs of
uroguanylin, on amelioration of colitis in murine models. METHODS: The cyclic guanosine …
uroguanylin, on amelioration of colitis in murine models. METHODS: The cyclic guanosine …
[HTML][HTML] Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice
AIM To evaluate the effect of orally administered plecanatide on colorectal dysplasia in
Apc+/Min-FCCC mice with dextran sodium sulfate (DSS)-induced inflammation. METHODS …
Apc+/Min-FCCC mice with dextran sodium sulfate (DSS)-induced inflammation. METHODS …
Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis
GM Pitari - Drug design, development and therapy, 2013 - Taylor & Francis
Agonists of the transmembrane intestinal receptor guanylyl cyclase C (GCC) have recently
attracted interest as promising human therapeutics. Peptide ligands that can specifically …
attracted interest as promising human therapeutics. Peptide ligands that can specifically …
Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses
K Shailubhai, S Comiskey, JA Foss, R Feng… - Digestive diseases and …, 2013 - Springer
Purpose Plecanatide, an analogue of uroguanylin, activates the guanylate cyclase C (GC-C)
receptor found on the GI mucosal epithelial cells, leading to secretion of fluid, facilitating …
receptor found on the GI mucosal epithelial cells, leading to secretion of fluid, facilitating …
[PDF][PDF] Plecanatide, a guanylate cyclase-C agonist, improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study [poster …
K Shailubhai, L Barrow, C Talluto… - Poster presented at …, 2011 - salixmedical.com
Plecanatide, a Guanylate Cyclase-C Agonist, Improves Bowel Habits and Symptoms
Associated with Chronic Constipation in a Phase I Page 1 Plecanatide, a Guanylate Cyclase-C …
Associated with Chronic Constipation in a Phase I Page 1 Plecanatide, a Guanylate Cyclase-C …
[HTML][HTML] Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
AIM To investigate the effects of plecanatide and dolcanatide on maintenance of
paracellular permeability, integrity of tight junctions and on suppression of visceral …
paracellular permeability, integrity of tight junctions and on suppression of visceral …
[HTML][HTML] Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′, 5′-monophosphate
Background & Aims Linaclotide is a minimally absorbed agonist of guanylate cyclase-C
(GUCY2C or GC-C) that reduces symptoms associated with irritable bowel syndrome with …
(GUCY2C or GC-C) that reduces symptoms associated with irritable bowel syndrome with …
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by
abdominal pain and altered bowel habit that affects~ 11% of the global population. Over the …
abdominal pain and altered bowel habit that affects~ 11% of the global population. Over the …
Therapeutically targeting guanylate cyclase‐C: computational modeling of plecanatide, a uroguanylin analog
A Brancale, K Shailubhai, S Ferla… - Pharmacology …, 2017 - Wiley Online Library
Plecanatide is a recently developed guanylate cyclase‐C (GC‐C) agonist and the first
uroguanylin analog designed to treat chronic idiopathic constipation (CIC) and irritable …
uroguanylin analog designed to treat chronic idiopathic constipation (CIC) and irritable …
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract
AP Bryant, RW Busby, WP Bartolini, EA Cordero… - Life sciences, 2010 - Elsevier
AIMS: Linaclotide is an orally administered 14-amino acid peptide being developed for the
treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic …
treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic …